Home › Funds › LETKO, BROSSEAU & ASSOCIATES INC › GSK

LETKO, BROSSEAU & ASSOCIATES INC position in GSK

GSK PLC · Health Care

LETKO, BROSSEAU & ASSOCIATES INC reported holding 1,617,928 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$77.9M, representing 1.13% of its reported portfolio and ranking #34 among its reported holdings. LETKO, BROSSEAU & ASSOCIATES INC has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.62M sh
Reported value held$77.94M
Portfolio Weight1.13%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How LETKO, BROSSEAU & ASSOCIATES INC's GSK position evolved

LETKO, BROSSEAU & ASSOCIATES INC first disclosed a stake in GSK in Q3 2023 at 1,197,968 shares (US$43.4M). The position peaked in Q1 2026 at 1,644,613 shares, worth US$90.8M. Across 13 filings, LETKO, BROSSEAU & ASSOCIATES INC increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 1,617,928 shares valued at US$77.9M. Notable position changes include a 33% increase in Q4 2024 (shares rose 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.20M $43.43M New
Q4 2023 1.18M $43.73M Reduce
Q1 2024 1.18M $50.51M Hold
Q2 2024 1.18M $45.59M Add
Q3 2024 1.22M $50.07M Add
Q4 2024 1.62M $54.90M Add
Q1 2025 1.62M $62.74M Hold
Q2 2025 1.66M $63.79M Add
Q3 2025 1.68M $72.33M Add
Q4 2025 1.67M $82.14M Hold
Q1 2026 1.64M $90.77M Reduce
Q2 2026 1.62M $85.17M Reduce
Q3 2026 1.62M $77.94M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GSK and 13F data

GSK (GSK PLC) is a Health Care company. 20 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GSK

All GSK fund holders →

FAQ

How long has LETKO, BROSSEAU & ASSOCIATES INC held GSK?

LETKO, BROSSEAU & ASSOCIATES INC has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is LETKO, BROSSEAU & ASSOCIATES INC's current position in GSK?

As of Q3 2026, LETKO, BROSSEAU & ASSOCIATES INC holds 1.62M shares of GSK (GSK PLC), valued at $77.94M, representing 1.13% of its reported portfolio and ranking #34.

Has LETKO, BROSSEAU & ASSOCIATES INC been buying or selling GSK?

In the latest 13F filing (Q3 2026), LETKO, BROSSEAU & ASSOCIATES INC held unchanged its position in GSK. The position peaked in Q1 2026 at 1.64M shares.

Which other funds hold GSK?

Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.